Clinical Trial Detail

NCT ID NCT03599453
Title Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Roswell Park Cancer Institute
Indications

triple-receptor negative breast cancer

Therapies

Celecoxib + Interferon alpha-2b + Pembrolizumab + Rintatolimod

Age Groups: adult senior

No variant requirements are available.